ACS Medicinal Chemistry Letters · 2012 · 42 citations · 22 references
MedicineMedicinal ChemistryPharmacologyClinical PharmacologyDrug DiscoveryNeuropharmacologyHeadache DisordersMigraine PharmacotherapyPotency OptimizationReceptor PharmacologyCalcitonin Gene-related Peptide AntagonistsIn Vivo Efficacy TestingMigraine PharmacologyNeuropeptide AntagonistsRelative Oral Bioavailability
Calcitonin gene-related peptide (CGRP) receptor antagonists have been clinically shown to be effective in the treatment of migraine, but identification of potent and orally bioavailable compounds has been challenging. Herein, we describe the conceptualization, synthesis, and preclinical characterization of a potent, orally active CGRP receptor antagonist 5 (BMS-846372). Compound 5 has good oral bioavailability in rat, dog, and cynomolgus monkeys and overall attractive preclinical properties including strong (>50% inhibition) exposure-dependent in vivo efficacy in a marmoset migraine model.
22